Market News

We screen for sub-$50M biotech companies with near-term regulatory events that could move the needle. Here are five names worth watching.

When executives buy their own stock with real money, it signals conviction. Here are the most significant insider purchases across the small-cap universe this month.

Academic research consistently shows that the smallest stocks deliver the highest long-term returns. We break down why — and the risks involved.

Q4 earnings are rolling in for small companies. We highlight the biggest beats, the biggest misses, and what the trends tell us about the small-cap economy.